GeoVax Labs (NASDAQ: GOVX) has announced the expansion of its oncology development strategy to evaluate additional solid tumor targets for Gedeptin—its gene-directed enzyme prodrug therapy.
According to GeoVax, the initiative builds on checkpoint inhibitor momentum and landmark results from its KEYNOTE-689 clinical trial. In collaboration with its oncology advisory team, including the Winship Cancer Institute of Emory University, the company is evaluating the combination of Gedeptin with immune checkpoint inhibitors in preclinical models of several solid tumor types. These models are designed to validate Gedeptin’s mechanism—localized intratumoral cytotoxicity that also primes systemic immune responses—in tumor settings beyond head and neck cancer such as triple negative breast cancer and cutaneous malignancies.
In a statement, David A. Dodd, chairman and CEO of GeoVax, commented, “We view the expansion of Gedeptin development beyond head and neck cancer as addressing a critically important area of solid tumor cancer therapy and a major value-creation opportunity. By leveraging the strengths of our oncology advisors and validated checkpoint inhibitor backbones, we aim to evaluate that Gedeptin’s tumor-debulking and immune-priming effects can potentially improve outcomes in a broader range of solid tumor cancers. The KEYNOTE-689 results provide important context, showing how immune-sensitizing strategies like Gedeptin are increasingly vital to maximizing checkpoint efficacy.”
Dr. Kelly T. McKee, CMO, added, “Our preclinical efforts will provide in-vivo proof of concept for expanding Gedeptin-checkpoint inhibitor combination therapy into additional solid tumor types. This is a natural evolution of our program and ensures we remain positioned at the forefront of immuno-oncology innovation.”
